The efficacy of modified luteal phase support with intramuscular progesterone in IVF/ICSI cycles: a retrospective observational study

被引:1
作者
Conforti, A. [1 ]
Strina, I. [1 ]
Mollo, A. [1 ]
Amoroso, R. [1 ]
Marrone, V. [1 ]
Alviggi, C. [1 ]
Marci, R. [2 ]
De Placido, G. [1 ]
机构
[1] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Naples, Italy
[2] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy
关键词
GnRH agonist; Ovarian triggering; hCG; IVF; HUMAN CHORIONIC-GONADOTROPIN; FINAL OOCYTE MATURATION; OVARIAN HYPERSTIMULATION SYNDROME; HORMONE GNRH AGONIST; LUTEINIZING-HORMONE; ANTAGONIST; INDUCTION; STIMULATION; COMBINATION; OVULATION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: The use of gonado-tropin-releasing hormone agonist for ovulation triggering has become an intriguing topic in the last few years. As long as adequate luteal phase support is provided, it may be a valuable alternative to standard hCG triggering, associated with a significant reduction in OHSS incidence. Several luteal phase support options have been proposed, but few studies have addressed the issue of the appropriate route for progesterone administration to women triggered with GnRHa. The aim of the study was to evaluate the effect of GnRHa triggering on IVF/ICSI outcomes, using modified luteal phase support with intramuscular progesterone. PATIENTS AND METHODS: A retrospective study was carried out between January 2014 and December 2015, comparing the reproductive outcome in GnRHa triggered women given modified luteal phase support with intramuscular progesterone (Group A) with the outcome in women triggered with standard hCG (Group B) in IVF/ICSI cycles. RESULTS: 200 (Group A n = 100; Group B n = 100) consecutive normoresponder women were included. No differences with respect to Age, BMI, basal FSH, basal Estradiol and infertility diagnosis were observed between groups. Increased numbers of retrieved oocytes (8.1 +/- 3.3 versus 6.8 +/- 3.5, p = 0.009) and mature oocytes (5.8 +/- 2.6 versus 5.1 +/- 2.7, p = 0.03) were detected in Group A compared with Group B. Implantation, biochemical pregnancy and ongoing pregnancy rates were similar. CONCLUSIONS: Our findings confirmed that the GnRHa triggering strategy is associated with increased number of oocytes retrieved and of mature oocytes even in normoresponder women. Moreover, in these patients, the use of intramuscular progesterone during luteal phase support achieved satisfactory IVF outcomes.
引用
收藏
页码:657 / 661
页数:5
相关论文
共 19 条
[1]   Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates [J].
Acevedo, Belen ;
Gomez-Palomares, Jose Luis ;
Ricciarelli, Elisabetta ;
Hernandez, Eleuterio R. .
FERTILITY AND STERILITY, 2006, 86 (06) :1682-1687
[2]   Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment [J].
Beckers, NGM ;
Macklon, NS ;
Eijkemans, MJ ;
Ludwig, M ;
Felberbaum, RE ;
Diedrich, K ;
Bustion, S ;
Loumaye, E ;
Fauser, BCJM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4186-4192
[3]   The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study [J].
Engmann, Lawrence ;
DiLuigi, Andrea ;
Schmidt, David ;
Nulsen, John ;
Maier, Donald ;
Benadiva, Claudio .
FERTILITY AND STERILITY, 2008, 89 (01) :84-91
[4]   GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis [J].
Engmann, Lawrence ;
Benadiva, Claudio ;
Humaidan, Peter .
REPRODUCTIVE BIOMEDICINE ONLINE, 2016, 32 (03) :274-285
[5]   Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach [J].
Garcia-Velasco, Juan A. ;
Motta, Leticia ;
Lopez, Ana ;
Mayoral, Mercedes ;
Cerrillo, Maria ;
Pacheco, Alberto .
FERTILITY AND STERILITY, 2010, 94 (07) :2820-2823
[6]   GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles:: a prospective randomized study [J].
Humaidan, P ;
Bredkjær, HE ;
Bungum, L ;
Bungum, M ;
Grondahl, ML ;
Westergaard, L ;
Andersen, CY .
HUMAN REPRODUCTION, 2005, 20 (05) :1213-1220
[7]   GnRH agonist for triggering of final oocyte maturation: time for a change of practice? [J].
Humaidan, P. ;
Kol, S. ;
Papanikolaou, E. G. .
HUMAN REPRODUCTION UPDATE, 2011, 17 (04) :510-524
[8]   1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study [J].
Humaidan, Peter ;
Bredkjaer, Helle Ejdrup ;
Westergaard, Lars Grabou ;
Andersen, Claus Yding .
FERTILITY AND STERILITY, 2010, 93 (03) :847-854
[9]  
ITSKOVITZ J, 1991, FERTIL STERIL, V56, P213
[10]   Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice [J].
La Marca, Antonio ;
Sunkara, Sesh Kamal .
HUMAN REPRODUCTION UPDATE, 2014, 20 (01) :124-140